| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $3.0M | — |
| Cost of Revenue | $17.0M | — |
| R&D Expense | $745.0M | +10.2% |
| SG&A Expense | $142.0M | +29.1% |
| Operating Income | -$901.0M | -14.6% |
| Pre-tax Income | -$816.0M | -9.1% |
| Income Tax | $0 | — |
| Net Income | -$816.0M | -9.1% |
| EPS (Basic) | -$0.44 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $221.0M | +4.7% |
| Current Assets | $1.32B | +5.0% |
| Total Assets | $2.34B | +9.6% |
| Current Liabilities | $111.0M | +5.7% |
| Total Liabilities | $203.0M | -22.8% |
| Stockholders' Equity | $2.14B | +14.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$581.0M | +4.9% |
| Capital Expenditures | $31.0M | -8.8% |
| Investing Cash Flow | -$245.0M | -42.4% |
| Financing Cash Flow | $834.0M | +69.5% |
| Free Cash Flow | -$612.0M | +5.1% |
| EPS (Diluted) | -$0.44 | +4.3% |